Clinical trial
Long-term Safety and Efficacy of Tenofovir Amibufenamide in Patients With HBeAg-positive or HBeAg-negative Chronic Hepatitis B - a Multicenter, Open-label Follow-up Study
NCT06743438 is registered in ClinicalTrials.gov with Jiangsu Hansoh Pharmaceutical Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Long-term Safety and Efficacy of Tenofovir Amibufenamide in Patients With HBeAg-positive or HBeAg-negative Chronic Hepatitis B - a Multicenter, Open-label Follow-up Study
- Lead sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Phase
- Phase 4
- Overall status
- Active, not recruiting
- Start date
- March 10, 2022
- Completion date
- September 30, 2029
- Enrollment
- 640 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.